153 related articles for article (PubMed ID: 29870644)
1. [Role of peginterferon-β-1a in the therapy of multiplex sclerosis].
Simó M; Iljicsov A
Ideggyogy Sz; 2017 Nov; 70(11-12):365-368. PubMed ID: 29870644
[TBL] [Abstract][Full Text] [Related]
2. Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis.
Hoy SM
CNS Drugs; 2015 Feb; 29(2):171-9. PubMed ID: 25666445
[TBL] [Abstract][Full Text] [Related]
3. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
Kieseier BC; Arnold DL; Balcer LJ; Boyko AA; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A; Sheikh SI; Calabresi PA
Mult Scler; 2015 Jul; 21(8):1025-35. PubMed ID: 25432952
[TBL] [Abstract][Full Text] [Related]
7. Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.
Newsome SD; Kieseier BC; Arnold DL; Shang S; Liu S; Hung S; Sabatella G
J Neurol; 2016 Sep; 263(9):1778-87. PubMed ID: 27314959
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study.
Arnold DL; You X; Castrillo-Viguera C
J Neurol; 2017 Aug; 264(8):1728-1734. PubMed ID: 28685353
[TBL] [Abstract][Full Text] [Related]
9. Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis.
Newsome SD; Guo S; Altincatal A; Proskorovsky I; Kinter E; Phillips G; You X; Sabatella G
Mult Scler Relat Disord; 2015 Jul; 4(4):350-7. PubMed ID: 26195056
[TBL] [Abstract][Full Text] [Related]
10. Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN.
Newsome SD; Scott TF; Arnold DL; Altincatal A; Naylor ML
Mult Scler Relat Disord; 2022 Jan; 57():103367. PubMed ID: 35158473
[TBL] [Abstract][Full Text] [Related]
11. Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.
Coyle PK; Shang S; Xiao Z; Dong Q; Castrillo-Viguera C
Mult Scler Relat Disord; 2018 May; 22():134-138. PubMed ID: 29679749
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.
Hu X; Cui Y; White J; Zhu Y; Deykin A; Nestorov I; Hung S
Br J Clin Pharmacol; 2015 Mar; 79(3):514-22. PubMed ID: 25265472
[TBL] [Abstract][Full Text] [Related]
13. An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists.
Kolb-Mäurer A; Sunderkötter C; Kukowski B; Meuth SG;
BMC Neurol; 2019 Jun; 19(1):130. PubMed ID: 31202258
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Hernandez L; Guo S; Kinter E; Fay M
J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF
J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845
[TBL] [Abstract][Full Text] [Related]
16. Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
Newsome SD; Mokliatchouk O; Castrillo-Viguera C; Naylor ML
Mult Scler Relat Disord; 2020 May; 40():101954. PubMed ID: 32078948
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN.
Newsome SD; Scott TF; Arnold DL; Nelles G; Hung S; Cui Y; Shang S; Naylor ML; Kremenchutzky M
Ther Adv Neurol Disord; 2018; 11():1756286418791143. PubMed ID: 30181778
[TBL] [Abstract][Full Text] [Related]
18. Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients.
Hang Y; Hu X; Zhang J; Liu S; Deykin A; Nestorov I
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):371-83. PubMed ID: 27299457
[TBL] [Abstract][Full Text] [Related]
19. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
[TBL] [Abstract][Full Text] [Related]
20. A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Tolley K; Hutchinson M; You X; Wang P; Sperling B; Taneja A; Siddiqui MK; Kinter E
PLoS One; 2015; 10(6):e0127960. PubMed ID: 26039748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
